Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(33%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Not yet recruiting1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

not_yet_recruiting133%

terminated133%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291

not_yet_recruitingphase_3

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

NCT07174492

terminatedphase_1

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04326283

Clinical Trials (3)

Showing 3 of 3 trials

NCT07142291Phase 2

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Recruiting

NCT07174492Phase 3

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Not Yet Recruiting

NCT04326283Phase 1

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3